Clinical Trial

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The OraGrowtH Phase 3 Trial is a multi-national trial. The goals of the trial are to study LUM-201 as a treatment for Pediatric Growth Hormone Deficiency (PGHD) in naive to treatment children and validate the LUM-201 predictive enrichment marker (LUM-201 PEM) strategy to select subjects likely to respond to therapy with daily oral LUM-201.
Protocol Amendment History 2 changes
notable Trial sites expanded: 29 -> 32 locations 2026-06-10
notable Trial sites expanded: 23 -> 26 locations 2026-04-21
Trial Details
NCT Number NCT06948214
Lead Sponsor Lumos Pharma
Conditions Growth Hormone Deficiency (GHD)
Enrollment 150 participants
Start Date 2026-05-20
Primary Completion 2027-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-06